Department of Internal Medicine, Medicine Institute, Cleveland Clinic, USA.
Cleve Clin J Med. 2010 Feb;77(2):113-6. doi: 10.3949/ccjm.77a.09173.
The US Food and Drug Administration has issued a warning that omeprazole (Prilosec) reduces the antiplatelet activity of clopidogrel (Plavix) by about 50%. However, the warning is based largely on ex vivo data. Preliminary results from a randomized clinical trial revealed no effect on cardiovascular outcomes when omeprazole was given with clopidogrel. We recommend that physicians continue to prescribe a proton pump inhibitor for patients receiving dual antiplatelet therapy who are at risk of gastrointestinal bleeding or have an indication for use of a proton pump inhibitor.
美国食品和药物管理局发出警告称，奥美拉唑（Prilosec）可使氯吡格雷（Plavix）的抗血小板活性降低约 50%。然而，该警告主要基于离体数据。一项随机临床试验的初步结果显示，奥美拉唑与氯吡格雷合用对心血管结局无影响。我们建议医生继续为接受双联抗血小板治疗且有胃肠道出血风险或有质子泵抑制剂使用指征的患者开具质子泵抑制剂。
